Growth
Baseimmune: A biotech breathing hope into the fight against fibrosis
- Growth
- Article
- 4 minutes read
Baseimmune is harnessing its antigen design platform to tackle fibrosis, a complex disease characterised by the formation of scar tissue. Starting with idiopathic pulmonary fibrosis, a lung condition, the team is driving towards enabling studies and clinical trials as they scale.
- Baseimmune is building pre-clinical programmes to tackle fibrosis, using its proprietary antigen design platform to generate the data needed to reach the clinic.
- By combining cutting-edge computational design with advanced protein engineering, the team can create bespoke antigens that address complex, chronic disease.
- Biotech is a space where cashflow comes in waves. Spending spikes as studies scale and CDMOs work ramps up. That’s why reliability liquidity is so important: it helps maintain momentum and removes a major operational distraction.
About Baseimmune: Building biotech to take on complex disease
Baseimmune is a pre-clinical biotech company with an ambitious goal. They’re using their antigen design platform – which combines computational design and advanced protein engineering – to tackle fibrosis, a complex disease characterised by the excessive formation of scar tissue.
The vision? Creating bespoke antigens that not only address the complexity of chronic diseases, but also transform patient outcomes through innovation.
Right now they’re in build mode. Co-founder and CSO Joshua Blight points out that the focus is on generating data. “We are utilising the technology we spent time developing to help address fibrosis”. The goal is to use that approach to develop new therapies for fibrosis, generating the evidence needed to select the strongest candidates and advance them towards clinical development.
Building a biotech business
Kevin Walton, CEO, Baseimmune"When developing biotech there’s an ebb and flow in terms of cash spend and outlays as you order materials but especially as you start doing bigger studies with CMDOs."
As CEO Kevin Walton points out, building FOAK solutions of this kind requires investment in peaks between the stages of R&D and product development.
But it’s not only about managing spending spikes. In a complex space like biotech, the ability to move quickly is crucial. Extensive use of AI and advanced computational design means things move fast.
We are honoured to work alongside this brilliant team of 23 to ensure that liquidity is “never an issue”, offering frictionless support so the scientists can do what they do best.
Biotech, banking, and the power of being on the same page
Joshua Blight, Co-Founder and CSO, Baseimmune"Trying to solve something as complex as fibrosis or other chronic diseases needs a stellar team across the entire spectrum - including monetary interactions."
Empowering the team to focus on their goals is an honour, as is being described as “proactive, pragmatic and sector fluent”.
We look forward to our continued relationship and seeing these extraordinary possibilities realised.
Any opinions expressed are merely opinions and not facts. All information in this document is for general informational purposes and not to be construed as professional advice or to create a professional relationship and the information is not intended as a substitute for professional advice. Nothing in this document takes into account your company’s individual circumstances. HSBC Innovation Banking does not make any representations or warranties with respect to the accuracy, applicability, fitness or completeness of this document and the material may not reflect the most current legal or regulatory developments. HSBC Innovation Banking disclaims all liability in respect to actions taken or not taken based on any or all of the contents in this document to the fullest extent permitted by law. Nothing relating to this material should be construed as a solicitation or offer, or recommendation, to acquire or dispose of any investment or to engage in any other transaction.
